Sorin Group, a manufacturer of medical technologies for cardiac surgery, has purchased Neurotech to expand its market of neuromodulation therapies for treating heart failure.
Neurotech's commercial products include implantable medical devices that stimulate the vagus nerve.
Experimental and pilot clinical studies have demonstrated that stimulation of the vagus nerve shows promising clinical effects on the cardiovascular function, and may become a potential treatment for heart failure.
In addition, the acquisition will complement Sorin's key heart failure treatment technical expertise and enhance its intellectual property position.
Sorin Group chief executive officer Andre-Michel Ballester said the deal confirms the company's commitment to the hemodynamic management of heart failure and its decision to enter the neuromodulation market.
"The Neurotech acquisition is another important step forward in our long-term growth initiatives announced in our recent Strategic Plan," Ballester added.
